Skip to Content
Merck
CN
  • A novel mutation in NF1 gene of patient with Neurofibromatosis type 1: A case report and functional study.

A novel mutation in NF1 gene of patient with Neurofibromatosis type 1: A case report and functional study.

Molecular genetics & genomic medicine (2021-03-26)
Tingting Zhang, Caiwei Jia, Zhiya Dong, Chuanyin Li, Wenli Lu
ABSTRACT

Neurofibromatosis type 1 is an autosomal dominant inherited disease and caused by NF1 gene mutation. Its clinical manifestations include multiple cafe´-au lait (CAL) spots, skinfold freckling, neurofibroma, bone dysplasia, learning disabilities, and an increased risk of malignancy. Here, we reported a Chinese patient bearing with a novel NF1 mutation (c.2064delGGATGCAGCGG/p.Gly672AsnfsTer24) and complaining mainly about bone phenotype. Functional studies found that this novel mutation caused the damage of NF1 mRNA and protein levels, and lost the inhibition on Ras/Erk signaling. A novel mutation in NF1 gene was identified and in vitro functional studies were performed, which provided a potential molecular mechanism to explain the bone maldevelopment of patients with neurofibromatosis type 1.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-phospho-ERK1 (pThr202/pTyr204) and ERK2 (pThr185/pTyr187) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
MONOCLONAL ANTI-ERK1/2 antibody produced in mouse, clone 784CT7.6.3, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
Anti-Pan-Ras Antibody, clone RAS 10, clone RAS 10, from mouse